We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.
- Authors
Mazzieri, Alessio; Porcellati, Francesca; Timio, Francesca; Reboldi, Gianpaolo
- Abstract
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, oxidative stress, inflammatory pathway, fibrotic signaling, and hemodynamic mechanisms) appears to drive the onset and progression of DKD. A growing understanding of the pathogenetic mechanisms, and the development of new therapeutics, is opening the way for a new era of nephroprotection based on precision-medicine approaches. This review summarizes the therapeutic options linked to specific molecular mechanisms of DKD, including renin-angiotensin-aldosterone system blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, endothelin receptor antagonists, and aldosterone synthase inhibitors. In a new era of nephroprotection, these drugs, as pillars of personalized medicine, can improve renal outcomes and enhance the quality of life for individuals with DKD.
- Subjects
ENDOTHELIN receptors; GLUCAGON-like peptide-1 receptor; INDIVIDUALIZED medicine; DRUG target; DIABETIC nephropathies; GLUCAGON-like peptide-1 agonists; THERAPEUTICS; MINERALOCORTICOID receptors
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 7, p3969
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25073969